Evidence map›Paper›PMID 39691463›Full record

ArticleChemical science2025

Biocatalytic synthesis of ribonucleoside analogues using nucleoside transglycosylase-2.

Admir Salihovic, Alex Ascham, Petja S Rosenqvist, Andrea Taladriz-Sender, Paul A Hoskisson, David R W Hodgson, Gideon Grogan, Glenn A Burley

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Admir SalihovicDepartment of Pure & Applied Chemistry, University of Strathclyde 295 Cathedral Street Glasgow G1 1XL UK glenn.burley@strath.ac.uk.ORCID https://orcid.org/0009-0004-4710-0145
Alex AschamDepartment of Chemistry, University of York Heslington York YO10 5DD UK gideon.grogan@york.ac.uk.ORCID https://orcid.org/0000-0002-1930-4667
Petja S RosenqvistDepartment of Chemistry, Durham University South Road Durham DH1 3LE UK.
Andrea Taladriz-SenderDepartment of Pure & Applied Chemistry, University of Strathclyde 295 Cathedral Street Glasgow G1 1XL UK glenn.burley@strath.ac.uk.ORCID https://orcid.org/0000-0002-8274-4761
Paul A HoskissonStrathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde 161 Cathedral Street Glasgow G4 0RE UK.ORCID https://orcid.org/0000-0003-4332-1640
David R W HodgsonDepartment of Chemistry, Durham University South Road Durham DH1 3LE UK.ORCID https://orcid.org/0000-0003-4517-9166
Gideon GroganDepartment of Chemistry, University of York Heslington York YO10 5DD UK gideon.grogan@york.ac.uk.ORCID https://orcid.org/0000-0003-1383-7056
Glenn A BurleyDepartment of Pure & Applied Chemistry, University of Strathclyde 295 Cathedral Street Glasgow G1 1XL UK glenn.burley@strath.ac.uk.ORCID https://orcid.org/0000-0002-4896-113X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ribonucleosides are essential building blocks used extensively in antiviral and oligonucleotide therapeutics. A major challenge in the further development of nucleoside analogues for therapeutic applications is access to scalable and environmentally sustainable synthetic strategies. This study uses the type II nucleoside 2'-deoxyribosyltransferase from

Identifiers

PMID39691463
PMCPMC11647913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.